FrancophonIA/ELRC3.0 huggingface dataset:
English: The lyophilisate can appear as a fine powder, however handling can cause it to appear as a more heavy and lumpy lyophilisate than as a powdery lyophilisate due to the mechanical instability of the freeze drying cake.
Estonian: Lüofilisaat võib esineda peene pulbrina, kuid mehaanilise ebastabiilsuse tõttu võib selle käsitlemisel pulberjas lüofilisaat muutuda raskemaks ja tükilisemaks känkraks.
English: Reconstitution and dilution of the powder for concentrate for solution for infusion Dissolve the Carmustine (100 mg powder) with 3 ml of the supplied sterile refrigerated ethanol solvent in the primary packaging (brown glass vial).
Estonian: Infusioonilahuse kontsentraadi pulbri manustamiskõlblikuks muutmine ja lahjendamine Lahustage karmustiin (100 mg pulbrit) esmapakendis (pruun klaasviaal) komplekti kuuluva steriilse jahutatud 3 ml etanoollahustiga.
English: The 30 ml stock solution is to be diluted immediately by adding the 30 ml stock solution to either 500 ml 5% glucose or 500 ml sodium chloride 9 mg/ml (0.9%) solution for injection in glass containers.
Estonian: Saadud 30 ml lahust tuleb lahjendada viivitamatult, lisades 30 ml põhilahust kas 500 ml 5% glükoosile või 500 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusele klaaspakendites.
English: For dissolving purposes only
Estonian: Ainult lahustamiseks
English: Common (may affect up to 1 in 10 people) - Acute leukaemias and bone marrow dysplasias (abnormal development of the bone marrow).Symptoms may include bleeding from the gums, bone pain, fever, frequent infections, frequent or severe nosebleed, lumps caused by swollen lymph nodes in and around the neck, underarm, abdomen or groin, pale skin, shortness of breath, weakness, fatigue or a general decrease in energy; - Anaemia (decrease in the amount of red blood cells in the blood); - Encephalopathy (disorder of brain).
Estonian: Sümptomid võivad muu hulgas olla igemete veritsus, luuvalu, palavik, sagedased nakkused, sagedased või rasked ninaverejooksud, paistetanud lümfisõlmedest põhjustatud mügarikud kaelas ja kaelapiirkonnas, kaenlaalustes, kõhus või kubemes, kahvatu nahk, õhupuudus, nõrkus, väsimus või üldine energialangus; - aneemia (erütrotsüütide koguse vähenemine veres); - entsefalopaatia (ajuhäire).
English: Renal toxicity.
Estonian: Neerutoksilisus.
English: Gynecomastia.
Estonian: Günekomastia.
English: In combination with chemotherapeutic medicinal products reduced activity of antiepileptic medicinal products must be anticipated.
Estonian: Fenütoiin ja deksametasoon Kombineeritult kemoterapeutikumidega võib eeldada epilepsiaravimite vähenenud aktiivsust.
English: The 30 ml stock solution is to be diluted immediately by adding the 30 ml stock solution to either 500 ml glucose 50 mg/ml (5%) solution for injection or 500 ml sodium chloride 9 mg/ml (0.9%) solution for injection in glass containers.
Estonian: Saadud 30 ml lahust tuleb lahjendada viivitamatult, lisades 30 ml põhilahust kas 500 ml glükoosi 50 mg/ml (5% süstelahusele või 500 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusele klaaspakendites.
English: Carmustine is carcinogenic in rats and mice at doses less than the recommended human dose based on body surface area.
Estonian: Karmustiin on rottidele ja hiirtele kehapindala alusel soovitatavast inimannusest väiksema annuse manustamisel kantserogeenne.
English: Carmustine Obvius is a powder and solvent for concentrate for solution for infusion.
Estonian: Carmustine Obvius on infusioonilahuse kontsentraadi pulber ja lahusti.
English: You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Estonian: Kõrvaltoimetest võite ka ise teavitada riikliku teavitussüsteemi, mis on loetletud V lisas.
English: Solvent Ethanol, anhydrous.
Estonian: Lahusti etanool, veevaba.
English: The solvent is a colourless clear liquid supplied in a clear glass ampule.
Estonian: Lahusti on värvitu läbipaistev vedelik läbipaistvas klaasampullis.
English: Women of childbearing potential are advised to use effective contraception to avoid becoming pregnant whilst being treated with this medicine and for at least 6 months after treatment.
Estonian: Rasestumisvõimelistel naistel on soovitatav kasutada ravi ajal ja vähemalt 6 kuu jooksul pärast ravi lõppemist rasestumise vältimiseks tõhusaid rasestumisvastaseid vahendeid.
English: Each vial of powder for concentrate for solution for infusion contains 100 mg carmustine.
Estonian: Üks infusioonilahuse kontsentraadi pulbri viaal sisaldab 100 mg karmustiini.
English: After reconstitution and dilutionthe solution should be administered within 3 hours after reconstitution and dilution of the product.
Estonian: Pärast manustamiskõlblikuks muutmist ja lahjendamist tuleb lahus manustada 3 tunni jooksul.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING POWDER VIAL
Estonian: SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED PULBRIVIAAL
English: Doses subsequent to the initial dose should be adjusted according to the haematologic response of the patient to the preceding dose in both monotherapy as well as in combination therapy with other myelosuppressive medicinal products.
Estonian: Nii monoteraapias kui ka kombinatsioonravis teiste müelosupressiivsete ravimpreparaatidega tuleb algannusele järgnevaid annuseid kohandada vastavalt patsiendi hematoloogilisele vastusele eelnevale annusele.
English: After reconstitution and dilution, the solution should be administered within 3 hours after reconstitution and dilution of the product.
Estonian: Pärast manustamiskõlblikuks muutmist ja lahjendamist Pärast manustamiskõlblikuks muutmist ja lahjendamist tuleb lahus manustada kolme tunni jooksul.
English: Brain tumours (glioblastoma, Brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases
Estonian: ajutuumorid (glioblastoom, ajutüve glioomid, medulloblastoom, astrotsütoom ja ependümoom), ajumetastaasid; mitte-Hodgkini lümfoomi ja Hodgkini lümfoomi teise valiku ravina.
English: Carmustine Obvius 100 mg powder for concentrate for solution for infusion carmustine
Estonian: Carmustine Obviuse 100 mg infusioonilahuse kontsentraadi pulber karmustiin
English: Frequency Adverse reactions
Estonian: Seedetrakti häired
English: SOLVENT AMPOULE
Estonian: LAHUSTIAMPULL
English: Not known Extravasation hazard: vesicant
Estonian: Teadmata Ekstravasatsiooni oht: ville tekitav aine.
English: Carmustine Obvius 100 mg powder and solvent for concentrate for solution for infusion
Estonian: Carmustine Obvius 100 mg infusioonilahuse kontsentraadi pulber ja lahusti karmustiin
English: Powder and solvent for concentrate for solution for infusion 1 vial of 100 mg powder
Estonian: Infusioonilahuse kontsentraadi pulber ja lahusti 1 viaal 100 mg pulbriga 1 ampull 3 ml lahustiga
English: Powder No excipients.
Estonian: Pulber puudub.
English: Talk to your doctor, pharmacist or nurse before using Carmustine Obvius.
Estonian: Enne Carmustine Obviuse kasutamist pidage nõu arsti, apteekri või meditsiiniõega.
English: The infusion should last around 1 to 2 hours.
Estonian: Infusioon peab vältama 1-2 tundi.
English: What measures are being taken to ensure the safe and effective use of Kanuma?
Estonian: Mis meetmed võetakse, et tagada Kanuma ohutu ja efektiivne kasutamine?
English: However, further data are needed on the long-term benefits and safety of the medicine.
Estonian: Ravimi pikaajalise kasu ja ohutuse kohta on siiski vaja täiendavaid andmeid.
English: A risk management plan has been developed to ensure that Kanuma is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Kanuma võimalikult ohutu kasutamine.
English: What is Kanuma and what is it used for?
Estonian: Mis on Kanuma ja milleks seda kasutatakse?
English: Kanuma sebelipase alfa
Estonian: Kanuma alfasebelipaas
English: Kanuma should be started as early as possible after diagnosis and is intended for long-term use.
Estonian: Kanuma-raviga tuleks pärast diagnoosimist alustada võimalikult varakult ning see on näidustatud pikaajaliseks kasutamiseks.
English: If antibodies develop, Kanuma may not work effectively.
Estonian: Antikehade tekkimisel ei toimi Kanuma efektiivselt.
English: What are the risks associated with Kanuma?
Estonian: Mis riskid Kanumaga kaasnevad?
English: Regarding safety, no major issues have been identified and serious side effects were rare or manageable.
Estonian: Ohutusega seoses ei ole tuvastatud suuremaid probleeme ning raskeid kõrvalnähtusi esines harva ja need olid talutavad.
English: Why is Kanuma approved?
Estonian: Miks Kanuma heaks kiideti?
English: The most serious side effects with Kanuma (seen in around 3 patients in 100) are signs and symptoms of severe allergic reactions.
Estonian: Kanuma kõige tõsisemad kõrvalnähud (esinevad ligikaudu 3 patsiendil 100-st) on raskete allergiliste reaktsioonide nähud ja sümptomid.
English: Treatment should be given by a trained healthcare professional who can manage medical emergencies (such as a severe allergy).
Estonian: Kanuma-ravi peaks teostama väljaõppinud tervishoiutöötaja, kes suudab pakkuda erakorralist meditsiiniabi (näiteks raske allergia korral).
English: The second study involved 66 patients (children and adults) and compared Kanuma with placebo (a dummy treatment).
Estonian: Teises uuringus osales 66 patsienti (täiskasvanud ja lapsed) ja selles võrreldi Kanumat platseeboga (näiv ravim).
English: It is not intended to provide practical advice on how to use Kanuma.
Estonian: Hindamisaruandes ei anta Kanuma kasutamise praktilisi nõuandeid.
English: These include chest discomfort, red eyes, eyelid swelling, difficulty breathing, itchy rash, hives, flushing, runny nose, rapid heartbeat and rapid breathing.
Estonian: Need nähud ja sümptomid on muu hulgas ebamugavustunne rinnus, silmade punetus, lauturse, hingamisraskused, sügelev lööve, nõgeslööve, õhetus, eritis ninast, südametegevuse kiirenemine ja hingamise kiirenemine.
English: Other information about Kanuma
Estonian: Muu teave Kanuma kohta
English: The first study involved 9 infants with growth failure or other evidence of rapidly progressing disease in their first 6 months of life.
Estonian: Esimene uuring hõlmas 9 imikut, kellel esines(id) kasvupeetus või muud tõendid haiguse kiirest progresseerumisest esimesel 6 elukuul.
English: In this study, 31% of the patients given Kanuma (11 out of 36) achieved normal levels of ALT enzymes, compared with 7% of the patients given placebo (2 out of 30).
Estonian: Selles uuringus saavutas Kanuma-ravi saanud patsientidest 31% (11 patsienti 36-st) ALAT-ensüümide normaliseerumise, võrreldes 7%-ga (2 patsienti 30-st) platseebot saanud patsientidest.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Kanuma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Kanuma kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Kanuma's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Kanuma kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: The full EPAR and risk management plan summary for Kanuma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Kanuma kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Kanuma must not be used in patients who have had a life-threatening allergic reaction to the active substance which re-occurred after stopping and starting treatment again.
Estonian: Kanumat ei tohi kasutada patsientidel, kellel on toimeaine suhtes esinenud eluohtlik allergiline reaktsioon, mis on pärast ravi katkestamist ja taasalustamist uuesti tekkinud.
English: In addition, the company that markets Kanuma is carrying out a study in infants with rapidly progressing disease and will set-up a registry of patients of all ages to obtain further information on the long-term benefits and safety of Kanuma, in particular on the risk of allergic reactions and the development of antibodies against the medicine.
Estonian: Lisaks on Kanumat turustaval ettevõttel käsil uuring kiiresti progresseeruva haigusega imikutega ning ta koostab igas vanuses patsientide registri, et saada lisateavet Kanuma pikaajalise kasu ja ohutuse, eelkõige allergiliste reaktsioonide riski ning ravimivastaste antikehade tekke kohta.
English: Development of antibodies against the medicine has also been reported especially in infants.
Estonian: Teatatud on ka ravimivastaste antikehade tekkimisest, eelkõige imikutel.
English: It must also not be used in patients with life-threatening allergy to eggs or any of Kanuma's ingredients.
Estonian: Samuti ei tohi seda kasutada patsientidel, kellel on eluohtlik allergia muna või Kanuma mis tahes koostisosa suhtes.
English: The company will also provide educational material to all doctors expected to prescribe Kanuma, encouraging them to enroll patients in the registry and informing them of how to monitor patients for antibodies and manage patients who develop severe allergic reactions.
Estonian: Samuti varustab ettevõte teabematerjalidega kõik arstid, kes tõenäoliselt Kanumat määravad, innustades neid patsiente registrisse lisama ja teavitades, kuidas jälgida patsiente antikehade suhtes ning ravida patsiente, kellel tekivad rasked allergilised reaktsioonid.
English: When the enzyme is absent or present only in low levels, fats accumulate in the body's cells, causing symptoms such as growth failure and liver damage.
Estonian: Kui see ensüüm puudub või kui seda on vähe, kogunevad rasvad keharakkudesse ning põhjustavad selliseid sümptomeid nagu kasvupeetus ja maksakahjustus.
English: What benefits of Kanuma have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Kanuma kasulikkus?
English: Growth improvements were also observed in all 6 surviving infants.
Estonian: Kõigil 6 ellujäänud imikul paranes ka kasv.
English: The recommended dose is 1 mg per kilogram body weight given once every other week.
Estonian: Kanuma soovitatav annus on 1 mg kehamassi kilogrammi kohta, mida manustatakse infusioonina üks kord iga kahe nädala järel.
English: The CHMP considered that Kanuma led to significant improvements in survival in infants, and was effective at improving symptoms of the disease in patients of all ages.
Estonian: Inimravimite komitee leidis, et Kanuma parandas märkimisväärselt imikute elulemust ning leevendas tõhusalt haiguse sümptomeid igas vanuses patsientidel.
English: High levels of ALT enzymes are a sign of liver damage.
Estonian: ALAT-ensüümide suur sisaldus on maksakahjustuse näht.
English: Because the number of patients with lysosomal acid lipase deficiency is low, the disease is considered ‘rare', and Kanuma was designated an ‘orphan medicine' (a medicine used in rare diseases) on 17 December 2010.
Estonian: Et lüsosomaalse happelise lipaasi puudulikkusega patsientide arv on väike ja see haigus esineb harva, nimetati Kanuma 17. detsembril 2010 harvikravimiks.
English: The Committee noted the lack of any effective treatments for lysosomal acid lipase deficiency and the high mortality in infants with rapidly progressing disease.
Estonian: Komitee märkis, et puudub tulemuslik lüsosomaalse happelise lipaasi puudulikkuse ravi ja et kiiresti progresseeruva haigusega imikute suremus on suur.
English: The main measure of effectiveness was the proportion of patients who achieved normal levels of a liver enzyme called ALT after 5 months of treatment.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide osakaal, kes pärast 5 kuud kestnud ravi saavutasid maksaensüümi ALAT normaalse sisalduse.
English: The study showed that 6 out of the 9 infants given Kanuma survived to 1 year of age.
Estonian: Uuringutest nähtus, et Kanuma-ravi saanud 9 imikust 6 elas 1. eluaastani.
English: Sebelipase alfa replaces the missing enzyme, helping to break down fats and stopping them building up in the body's cells.
Estonian: Alfasebelipaas asendab puuduvat ensüümi ning aitab lagundada rasvu ja takistab nende kogunemist keharakkudes.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Kanuma, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Kanuma omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: How is Kanuma used?
Estonian: Kuidas Kanumat kasutatakse?
English: In patients who have rapidly progressing disease before 6 months of age, a dose of 1 mg/kg is given once a week instead of once every other week; in these patients the dose can be increased to 3 mg/kg once a week depending on the response to treatment.
Estonian: Kiiresti progresseeruva haigusega alla 6 kuu vanustele patsientidele antakse ravimit mitte iga kahe nädala järel, vaid üks kord nädalas annuses 1 mg/kg.
English: For practical information about using Kanuma, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Kanuma kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: How does Kanuma work?
Estonian: Kuidas Kanuma toimib?
English: For more information about treatment with Kanuma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Kanumaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For the full list of all side effects reported with Kanuma, see the package leaflet.
Estonian: Kanuma kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: This is an inherited disease caused by the lack of an enzyme called lysosomal acid lipase, which is needed to break down fats within cells.
Estonian: See on pärilik haigus, mida põhjustab ensüümi lüsosomaalse happelise lipaasi puudus; see ensüüm on vajalik rasvade lõhustamiseks rakus.
English: Treatment with Kanuma should be supervised by a doctor experienced in the treatment of lysosomal acid lipase deficiency, other metabolic diseases or liver diseases.
Estonian: Kanuma-ravi peaks toimima lüsosomaalse happelise lipaasi puudulikkuse, muude ainevahetushaiguste või maksahaiguste ravis kogenud arsti järelevalve all.
English: This is a summary of the European public assessment report (EPAR) for Kanuma.
Estonian: See on ravimi Kanuma Euroopa avaliku hindamisaruande kokkuvõte.
English: Kanuma has been studied in 2 main studies in patients with lysosomal acid lipase deficiency.
Estonian: Kanumat on lüsosomaalse happelise lipaasi puudulikkusega patsientidel uuritud 2 põhiuuringus.
English: The active substance in Kanuma, sebelipase alfa, is a copy of the enzyme that is lacking in patients with lysosomal acid lipase deficiency.
Estonian: Kanuma toimeaine alfasebelipaas on lüsosomaalse happelise lipaasi puudulikkusega patsientidel puuduva ensüümi koopia.
English: The medicine can only be obtained with a prescription.
Estonian: Kanuma on retseptiravim.
English: Kanuma is available as a concentrate to be made into a solution for infusion (drip) into a vein.
Estonian: Seda turustatakse infusioonilahuse (veeni tilgutatava lahuse) kontsentraadina.
English: Kanuma contains the active substance sebelipase alfa.
Estonian: Ravim sisaldab toimeainena alfasebelipaasi.
English: Kanuma is a medicine used to treat patients of all ages with lysosomal acid lipase deficiency.
Estonian: Kanuma on ravim, mida kasutatakse lüsosomaalse happelise lipaasi puudulikkusega igas vanuses patsientide raviks.
English: Cattle Intramuscular Vial (glass) 1 dose (2 ml)
Estonian: Intramuskulaarne Viaal (klaas) 1 annus (2 ml)
English: --1 Lipoteichoic acid (LTA) from Biofilm Adhesion Component (BAC) of Streptococcus uberis, strain 5616 ............................................................................................................. ≥ 1 RPU* *Relative Potency Units (ELISA)
Estonian: --1 Streptococcus uberis'e tüve 5616 biokile adhesioonikomponendist (BAC) pärinev lipoteihhoiinhape (LTA)
English: 20 vials
Estonian: 20 viaaliga 0 päeva
English: EU (MA) number Invente d name
Estonian: Väljamõeldu d nimetus
English: • if you become pregnant;
Estonian: • kui jääte rasedaks;
English: Do not use force.
Estonian: Ärge kasutage jõudu.
English: However, they should be considered in case of long term or repeated use of this product.
Estonian: Kuid nendega tuleb arvestada toote pikaajalisel või korduval kasutamisel.
English: Your doctor may decide to perform a physical examination.
Estonian: Arst võib otsustada teha arstliku läbivaatuse.
English: − Rinse the 2 pieces for 30 seconds under running water;
Estonian: − loputage mõlemat osa 30 sekundit jooksva vee all;
English: It is not known if this medicine affects fertility.
Estonian: Pole teada, kas ravim mõjutab viljakust.
English: The potential risk in humans is unknown.
Estonian: Võimalik oht inimesele pole teada.
English: − Take it to pieces;
Estonian: − võtke see osadeks;
English: Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Estonian: Teatage arstile või apteekrile, kui võtate, olete hiljuti võtnud või kavatsete võtta mis tahes muid ravimeid.
English: If it is less than 12 months since your last menstrual period or you are under 50 years old, you may still need to use additional contraception to prevent pregnancy.
Estonian: Kui teie viimasest menstruatsioonist on möödunud vähem kui 12 kuud või kui olete alla 50 aasta vana, võite ikka veel vajada täiendavaid vahendeid rasestumise vältimiseks.
English: • Hold the applicator between your thumb and middle finger.
Estonian: • Hoidke aplikaatorit pöidla ja keskmise sõrme vahel.
English: • you are seriously overweight (BMI >30 kg/m2);
Estonian: • olete tugevalt ülekaaluline (KMI >30 kg/m2);
English: • Regularly check your breasts.
Estonian: • Kontrollige rindu regulaarselt.
English: Therefore, if repeated, treatment should be reviewed at least annually.
Estonian: Seepärast tuleb ravi kordamisel see vähemalt kord aastas üle vaadata.
English: • you are unable to walk for a long time because of major surgery, injury or illness (see also section 3, If you need to have surgery);
Estonian: • te ei saa raske operatsiooni, vigastuse või haiguse tõttu pikka aega kõndida (vt ka lõik 3, kui vajate operatsiooni);
English: This may include an examination of your breasts and/or an internal examination, if necessary.
Estonian: See võib vajadusel hõlmata rindade läbivaatust ja/või sisemist uuringut.
English: B. Using the finger
Estonian: B. Sõrme kasutamine
English: Of note, this case was present before start of treatment and was bearing a BRCA1 mutation.
Estonian: Märkus: see juhtum oli olemas juba enne ravi algust ning hõlmas BRCA1-mutatsiooni.
English: Place the applicator on a clean surface.
Estonian: Pange aplikaator puhtale pinnale.
English: Keep it in a clean place.
Estonian: hoidke puhtas kohas.
English: #Overall risk ratio.
Estonian: #Üldine riskisuhe.
English: Additionally, you are advised to join mammography screening programs when offered to you.
Estonian: Lisaks on soovitatav liituda mammograafia sõeluuringute programmiga, kui seda pakutakse.
English: Carcinogenic and reproductive and development toxicity studies were not performed.
Estonian: Kartsinogeense ja reproduktiiv-/arengutoksilisuse uuringuid ei ole tehtud.
English: • If any of the following conditions are present, have occurred previously, and/or have been aggravated during pregnancy or previous hormone treatment, the patient should be closely supervised.
Estonian: • Kui mõni järgmistest seisunditest esineb, on varem esinenud ja/või on raseduse või varasema hormoonravi ajal halvenenud, tuleb patsienti hoolikalt jälgida.